Read-Gene S.A. (WSE:RDG)

Market Cap	51.17M
Revenue (ttm)	12.85M
Net Income (ttm)	-996.00K
Shares Out	11.79M
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	68
Average Volume	221
Open	4.340
Previous Close	4.340
Day's Range	4.340 - 4.340
52-Week Range	3.800 - 6.660
Beta	0.60
RSI	47.08
Earnings Date	May 9, 2025

About Read-Gene

Read-Gene S.A. engages in the detection, prevention, and treatment of various types of cancer. Its activities include chemoprevention, clinical tests, and genetic tests. Chemoprevention is the use of natural or synthetic substances to stop, reverse, or delay the process of developing cancer. The company conducts clinical trials in cancer patients; and provides genetic tests and genetic-oncological consultations to all patients for the most common cancers, such as breast, ovary, prostate, stomach, large intestine, and breast cancer. Read-Gene S....

• Industry: Biotechnology & Medical Research
• Sector: Healthcare
• Founded: 2005
• Employees: 22
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: RDG

Financial Performance

In 2024, Read-Gene's revenue was 12.85 million, an increase of 26.62% compared to the previous year's 10.15 million. Losses were -995,997, -26.03% less than in 2023.